Recursion Pharmaceuticals Inc (RXRX) Annual Income Statement (USD)
RXRX Quarterly Financials (USD)
Frequently Asked Questions About Recursion Pharmaceuticals Inc (RXRX) Stock
Recursion Pharmaceuticals Inc's (RXRX) last reported annual revenue was USD 44.58 Million.
Recursion Pharmaceuticals Inc's (RXRX) annual revenue growth rate based on the revenue reported in the past 5 years is : 147.73%
Recursion Pharmaceuticals Inc's(RXRX) is not profitable as of its last reported annual financials.
The net profit margin for Recursion Pharmaceuticals Inc's(RXRX) from its laster reported year is -735.99%
The return on equity (ROE) for Recursion Pharmaceuticals Inc's(RXRX) from its last reported annual financials is : -71.18%
The return on assets (ROA) for Recursion Pharmaceuticals Inc's(RXRX) from its last reported annual financials is : -34.35%
The return on invested capital (ROIC) for Recursion Pharmaceuticals Inc's(RXRX) from its last reported annual financials is : -72.76%
The Debt to Equity ratio for Recursion Pharmaceuticals Inc's(RXRX) from its last reported annual financials is : 0.24%
The dividend yield for Recursion Pharmaceuticals Inc's(RXRX) from its laster reported year is 0.00%
Recursion Pharmaceuticals Inc's(RXRX) has negative cash flow as of its last reported annual financials.
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for RXRX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
